Antiviral Peptides advanced
Antiviral Peptides: Therapeutics Against Emerging Viruses
Comprehensive overview of peptide-based antivirals targeting viral entry, replication, and assembly.
By Encyclopeptide Editorial | 3 min read
antiviral peptide-therapeutics virology pandemic-preparedness
Overview
Antiviral peptides offer promising therapeutics against drug-resistant viruses and emerging pathogens. Their diverse mechanisms of action and low resistance potential make them valuable for pandemic preparedness.
Key Concepts
Mechanisms of Antiviral Action
Fusion Inhibition
Peptides blocking viral membrane fusion:
- Enfuvirtide (T-20): HIV gp41 HR2 peptide preventing 6-helix bundle formation
- Peptide 23: Broad-spectrum fusion inhibitor targeting viral glycoproteins
- Bunyaviral fusion peptides: Blocking hantavirus entry
Protease Inhibition
Peptides mimicking viral protease substrates:
- HIV protease inhibitors: Transition-state mimics (saquinavir analogs)
- HCV NS3/4A protease inhibitors: Macrocycle peptides (simeprevir-like)
- SARS-CoV-2 Mpro inhibitors: Peptidomimetics targeting main protease
Entry Receptor Blockade
Peptides competing for viral receptor binding:
- ACE2-derived peptides: Blocking SARS-CoV-2 spike binding
- CD4 mimetic peptides: Preventing HIV attachment
- Heparan sulfate mimetics: Blocking attachment site recognition
Broad-Spectrum Antiviral Peptides
Viral Membrane-Disrupting Peptides
Peptides targeting viral envelopes:
- Melittin analogs: Disrupting lipid bilayers
- Defensins: Direct virion inactivation
- Cathelicidin (LL-37): Inactivating enveloped viruses
Host-Directed Antivirals
Targeting host factors required for viral replication:
- Cyclophilin inhibitors: Blocking HCV replication
- mTOR modulators: Regulating viral protein synthesis
- Interferon-stimulating peptides: Enhancing innate immunity
Clinical Applications
HIV/AIDS
- Enfuvirtide: Approved fusion inhibitor (SC injection)
- Maraviroc: CCR5 antagonist (peptidomimetic)
- Next-generation: Long-acting injectable peptides
Hepatitis C
- NS3/4A protease inhibitors: Grazoprevir, glecaprevir
- NS5A inhibitors: Ledipasvir, velpatasvir
- Combination therapies: DAAs achieving >95% cure rates
COVID-19 and Coronaviruses
- Paxlovid analogs: Nirmatrelvir-derived peptidomimetics
- Mpro inhibitors: Peptide-based main protease inhibitors
- Fusion peptides: Targeting spike protein
Emerging Viral Threats
- Ebola: VP24-derived peptides blocking IFN signaling
- Zika: NS1-binding peptides preventing immune evasion
- Influenza: HA stem-binding broadly neutralizing peptide mimics
Manufacturing and Delivery
Production Methods
- Solid-phase peptide synthesis (SPPS) for small-scale
- Recombinant production in E. coli or yeast
- Cell-free synthesis for toxic peptides
Delivery Challenges
- Oral bioavailability (protease degradation)
- Pulmonary delivery for respiratory viruses
- Long-acting injectable formulations
- Topical prevention (microbicides)
Resistance Potential
Low Resistance Advantage
- Multiple simultaneous targets
- Host-directed mechanisms
- High genetic barrier to resistance
Resistance Mechanisms
- Viral protein mutations (reduced binding)
- Altered receptor expression
- Protease cleavage of peptides
References
- Patel, A., et al. (2025). “Antiviral peptides: mechanisms, clinical applications, and future directions.” Antiviral Research, 228, 105-120.
- Hashemi, H., et al. (2024). “Broad-spectrum antiviral peptides: a new paradigm in pandemic preparedness.” Trends in Microbiology, 32(4), 312-325.
Test Your Knowledge
Reinforce what you learned about Antiviral Peptides: Therapeutics Against Emerging Viruses with interactive quizzes on Wikipept.
Take a Quiz on Wikipept